Cargando…

Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone

Mast cell tumors (MCTs) are common neoplasms in dogs, and treatments for these diseases include surgery, polychemotherapy and targeted therapy with tyrosine kinase inhibitors. This study aimed to evaluate the response and the adverse events of treatment with imatinib mesylate (IM) compared to conven...

Descripción completa

Detalles Bibliográficos
Autores principales: Macedo, Thais Rodrigues, de Queiroz, Genilson Fernandes, Casagrande, Thaís Andrade Costa, Alexandre, Pâmela Almeida, Brandão, Paulo Eduardo, Fukumasu, Heidge, Melo, Samanta Rios, Dagli, Maria Lucia Zaidan, Pinto, Ana Carolina B. C. Fonseca, Matera, Julia Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834544/
https://www.ncbi.nlm.nih.gov/pubmed/35159380
http://dx.doi.org/10.3390/cells11030571
_version_ 1784649213376724992
author Macedo, Thais Rodrigues
de Queiroz, Genilson Fernandes
Casagrande, Thaís Andrade Costa
Alexandre, Pâmela Almeida
Brandão, Paulo Eduardo
Fukumasu, Heidge
Melo, Samanta Rios
Dagli, Maria Lucia Zaidan
Pinto, Ana Carolina B. C. Fonseca
Matera, Julia Maria
author_facet Macedo, Thais Rodrigues
de Queiroz, Genilson Fernandes
Casagrande, Thaís Andrade Costa
Alexandre, Pâmela Almeida
Brandão, Paulo Eduardo
Fukumasu, Heidge
Melo, Samanta Rios
Dagli, Maria Lucia Zaidan
Pinto, Ana Carolina B. C. Fonseca
Matera, Julia Maria
author_sort Macedo, Thais Rodrigues
collection PubMed
description Mast cell tumors (MCTs) are common neoplasms in dogs, and treatments for these diseases include surgery, polychemotherapy and targeted therapy with tyrosine kinase inhibitors. This study aimed to evaluate the response and the adverse events of treatment with imatinib mesylate (IM) compared to conventional therapy using vinblastine and prednisolone (VP) in canine cutaneous MCTs. Twenty-four dogs were included in the study; 13 animals were treated with IM and 11 with VP. Tumor tissue samples were submitted for histological diagnosis, grading and KIT immunostaining. The response to treatment was assessed by tomographic measurements according to VCOG criteria. Adverse events were classified according to VCOG-CTCAE criteria. The IM and VP groups had dogs with similar breeds, gender, ages, MCT localization, WHO stages and lymph node metastasis profiles. Most MCTs were grade 2/low and had KIT- patterns 2 and 3. The objective response rate (ORR) was significantly higher (30.79%) in the IM group then in VP group (9.09%). Adverse events (AE) in IM group were all grade 1, significantly different from VP. In conclusion, IM presented better ORR and less severe adverse events when compared to VP, representing a suitable option for the treatment of low-grade canine MCTs.
format Online
Article
Text
id pubmed-8834544
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88345442022-02-12 Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone Macedo, Thais Rodrigues de Queiroz, Genilson Fernandes Casagrande, Thaís Andrade Costa Alexandre, Pâmela Almeida Brandão, Paulo Eduardo Fukumasu, Heidge Melo, Samanta Rios Dagli, Maria Lucia Zaidan Pinto, Ana Carolina B. C. Fonseca Matera, Julia Maria Cells Article Mast cell tumors (MCTs) are common neoplasms in dogs, and treatments for these diseases include surgery, polychemotherapy and targeted therapy with tyrosine kinase inhibitors. This study aimed to evaluate the response and the adverse events of treatment with imatinib mesylate (IM) compared to conventional therapy using vinblastine and prednisolone (VP) in canine cutaneous MCTs. Twenty-four dogs were included in the study; 13 animals were treated with IM and 11 with VP. Tumor tissue samples were submitted for histological diagnosis, grading and KIT immunostaining. The response to treatment was assessed by tomographic measurements according to VCOG criteria. Adverse events were classified according to VCOG-CTCAE criteria. The IM and VP groups had dogs with similar breeds, gender, ages, MCT localization, WHO stages and lymph node metastasis profiles. Most MCTs were grade 2/low and had KIT- patterns 2 and 3. The objective response rate (ORR) was significantly higher (30.79%) in the IM group then in VP group (9.09%). Adverse events (AE) in IM group were all grade 1, significantly different from VP. In conclusion, IM presented better ORR and less severe adverse events when compared to VP, representing a suitable option for the treatment of low-grade canine MCTs. MDPI 2022-02-07 /pmc/articles/PMC8834544/ /pubmed/35159380 http://dx.doi.org/10.3390/cells11030571 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Macedo, Thais Rodrigues
de Queiroz, Genilson Fernandes
Casagrande, Thaís Andrade Costa
Alexandre, Pâmela Almeida
Brandão, Paulo Eduardo
Fukumasu, Heidge
Melo, Samanta Rios
Dagli, Maria Lucia Zaidan
Pinto, Ana Carolina B. C. Fonseca
Matera, Julia Maria
Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone
title Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone
title_full Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone
title_fullStr Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone
title_full_unstemmed Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone
title_short Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone
title_sort imatinib mesylate for the treatment of canine mast cell tumors: assessment of the response and adverse events in comparison with the conventional therapy with vinblastine and prednisone
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834544/
https://www.ncbi.nlm.nih.gov/pubmed/35159380
http://dx.doi.org/10.3390/cells11030571
work_keys_str_mv AT macedothaisrodrigues imatinibmesylateforthetreatmentofcaninemastcelltumorsassessmentoftheresponseandadverseeventsincomparisonwiththeconventionaltherapywithvinblastineandprednisone
AT dequeirozgenilsonfernandes imatinibmesylateforthetreatmentofcaninemastcelltumorsassessmentoftheresponseandadverseeventsincomparisonwiththeconventionaltherapywithvinblastineandprednisone
AT casagrandethaisandradecosta imatinibmesylateforthetreatmentofcaninemastcelltumorsassessmentoftheresponseandadverseeventsincomparisonwiththeconventionaltherapywithvinblastineandprednisone
AT alexandrepamelaalmeida imatinibmesylateforthetreatmentofcaninemastcelltumorsassessmentoftheresponseandadverseeventsincomparisonwiththeconventionaltherapywithvinblastineandprednisone
AT brandaopauloeduardo imatinibmesylateforthetreatmentofcaninemastcelltumorsassessmentoftheresponseandadverseeventsincomparisonwiththeconventionaltherapywithvinblastineandprednisone
AT fukumasuheidge imatinibmesylateforthetreatmentofcaninemastcelltumorsassessmentoftheresponseandadverseeventsincomparisonwiththeconventionaltherapywithvinblastineandprednisone
AT melosamantarios imatinibmesylateforthetreatmentofcaninemastcelltumorsassessmentoftheresponseandadverseeventsincomparisonwiththeconventionaltherapywithvinblastineandprednisone
AT daglimarialuciazaidan imatinibmesylateforthetreatmentofcaninemastcelltumorsassessmentoftheresponseandadverseeventsincomparisonwiththeconventionaltherapywithvinblastineandprednisone
AT pintoanacarolinabcfonseca imatinibmesylateforthetreatmentofcaninemastcelltumorsassessmentoftheresponseandadverseeventsincomparisonwiththeconventionaltherapywithvinblastineandprednisone
AT materajuliamaria imatinibmesylateforthetreatmentofcaninemastcelltumorsassessmentoftheresponseandadverseeventsincomparisonwiththeconventionaltherapywithvinblastineandprednisone